Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S7.47
P/E—
Fwd P/E24.98
PEG1.84
52W— – —
RSI—
Target$100.96 (+19.7%)
Beta0.85
Div—
Loading chart…
RSI ()
Loading patterns…
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 31
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
5Bullish
6Bearish
0Neutral
Key Signals 1
▼ Double Top
Major reversal
2026-09-08 · $88.79
Two peaks ~$93.43 — bearish reversal confirmed
Learn more →
Momentum Signals 10
▲ MACD Bullish Crossover
▲ Bull Flag
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
88%
7/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$100.96
+19.7% upside
Low $84
—
High $110
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
77.84%Last 12 Months
Operating Margin
29.84%Last 12 Months
Return on Equity
9.18%Last 12 Months
Revenue Growth
13.60%Year over Year
Free Cash Flow
1.23BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
6.57Most Recent Quarter
Current Ratio
4.52Most Recent Quarter
Cash
4.25BMost Recent Quarter
Total Debt
704.40MMost Recent Quarter
Net Debt
—Most Recent Quarter
How EW Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 48.63B |
| Enterprise Value | 45.19B |
| Trailing P/E | 51.45 |
| Forward P/E | 24.98 |
| PEG Ratio (5yr) | 1.84 |
| Price/Sales (ttm) | 7.47 |
| Price/Book (mrq) | 4.58 |
| EV/Revenue | 6.94 |
| EV/EBITDA | 22.63 |
Share Statistics
| Avg Vol (3m) | 4.15M |
| Shares Outstanding | 576.40M |
| Float | 574.50M |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 95.76% |
| Short Ratio | 2.94 |
| Short % of Float | 1.78% |
Profitability
| Gross Margin | 77.84% |
| Operating Margin (ttm) | 29.84% |
| Profit Margin | 15.43% |
| Return on Assets (ttm) | 8.37% |
| Return on Equity (ttm) | 9.18% |
Income Statement
| Revenue (ttm) | 6.51B |
| Revenue Growth (yoy) | 13.60% |
| Gross Profit (ttm) | 5.07B |
| EBITDA | 2.00B |
| Net Income (ttm) | 979.90M |
| Diluted EPS (ttm) | 1.64 |
| EPS Growth (yoy) | -25.40% |
Balance Sheet
| Total Cash (mrq) | 4.25B |
| Total Debt (mrq) | 704.40M |
| Debt / Equity (mrq) | 6.57 |
| Current Ratio (mrq) | 4.52 |
| Book Value / Share | 18.41 |
| Operating CF (ttm) | 1.72B |
| Free Cash Flow (ttm) | 1.23B |
Trading & Dividends
| Beta (5Y) | 0.85 |
| 50-Day MA | 89.38 |
| 200-Day MA | 84.98 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
No dividend history available for EW.
Ownership Breakdown
Institutional 95.76%
Insider 0.19%
Public 4.0%
Short Interest
1.78% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in EW in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|